Cartesian Therapeutics (RNAC) Misses Q1 EPS by 68c

Cartesian Therapeutics (NASDAQ: RNAC) reported Q1 EPS of ($0.68). Revenue for the quarter came in at $1.1 million.

For earnings history and earnings-related data on Cartesian Therapeutics (RNAC) click here.

You May Also Be Interested In

• Tesla (TSLA) PT Raised to $400 at Jefferies
• Hinge Health Inc (HNGE) PT Raised to $108 at Morgan Stanley
• Citi initiates Bel Fuse coverage with Buy rating, $325 target